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A transcript coding for a partially duplicated form of α α7 nicotinic acetylcholine receptor is absent from the CD4 + T-lymphocytes of patients with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels, which belong to a superfamily of homologous receptors. The nAChRs are expressed in the mammalian brain in the form of hetero-or homomeric structures consisting of four transmembrane regions (TM1 through TM4) surrounding a centrally located ion channel [33] . These structures are composed of a number of subunits of multiple subtypes. To date, 9 distinct genes encoding neuronal nAChR subunits (α2 to α10 and β2 to β4) have been found in various species [29] . In the mammalian brain, two types of nAChRs have been distinguished based on their affinity for nicotine or α-bungaroto xin as ligands. Functional receptors as homomers can be obtained by assembling α7, α8 and α9 subunits, whereas other α subunits may co-assemble with at least one type of β subunit to form heteromers [17] . The second type of nAChR, composed exclusively of α7 subunits, exhibits low affinity for nicotine and high affinity for α-bungarotoxin [6] . The nAChRs containing the α7 subunit are expressed throughout the entire central nervous system. These receptors are localised pre-and postsynaptically and modulate both the excitatory and inhibitory pathways. They are predominantly located in cholinergic and non-cholinergic presynaptic terminals, such as GABA-ergic interneurons [12] . The α7 nAChRs are also found in nerve terminals located in peripheral tissues and are involved in neuropeptide release and protection against inflammatory processes [32] . Of particular interest is the function of nAChRs in peripheral blood lymphocytes (PBLs) [21] . These cells produce acetylcholine (ACh), which may exert its effect through autocrine or paracrine transmission. Different nAChR subunits have been detected in blood cells, but their patterns of expression as well as their functions remain largely unknown. It has been reported that α2, α5 and α7 nAChR subunits are expressed in PBLs, raising the possibility that these subunits may serve as a marker of some neurological diseases [44] . However, the expression of genes encoding the α4 and β3 subunits have not been detected in the majority of cell lines derived from peripheral blood tested so far [25] .
The genes encoding nAChR subunits have also emerged as candidate genes for inherited idiopathic epilepsies. Mutations of the genes coding for the nAChR α4 (CHRNA4), α2 (CHRNA2), or β2 (CHRNB2) subunits are associated with familial forms of partial epilepsies, classified as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) [22, 35, 40] . In ADNFLE patients, mutations in the genes encoding these subunits are located within TM1 (CHRNA2 mutation), within or directly adjacent to TM2 (CHRNA4 mutations), or are equally distributed between TM2 and TM3 (CHRNB2 mutations). The function of mutant nAChRs has been extensively studied in vitro with the use of electrophysiological methods [39] . In vivo PET studies of the distribution of the mutated receptor in the brain of ADNFLE patients have demonstrated decreased density of nAChR in the prefrontal cortex, consistent with focal epilepsy involving the frontal lobe [36] .
A number of loci have been reported for juvenile myoclonic epilepsy (JME), including our populationbased study testing the hypothesis that the variants of CHRNA4 confer genetic susceptibility to this form of epilepsy [41] . Linkage studies provide evidence that the gene encoding the α7 subunit of nAChR (CHRNA7) is located within the polymorphic locus on chromosome 15q14. This locus, called EJM2 (OMIM ID: 604827), has been shown to contribute to genetic susceptibility to JME in the majority of studied families [50] . Susceptibility loci for the common idiopathic generalized epilepsies (IGEs) -comprising of JME, juvenile absence epilepsy (JAE), childhood absence epilepsy (CAE), and benign epilepsy of childhood with centrotemporal spikes (BECT) -have also been mapped to the 15q13-q14 region [13, 24, 31, 43] . A particularly high expression of CHRNA7 in the reticular thalamus [4] indicates this gene's role in modulating thalamocortical pathways, which participate in the generation of the primarily generalized seizures seen in IGEs [3] .
Out of the nicotinic acetylcholine receptors, the α7 nAChRs are of particular importance in the pathogenesis of Alzheimer's disease (AD). Our investigations A transcript coding for a partially duplicated form of α7 nicotinic acetylcholine receptor is absent from the CD4 + T-lymphocytes of patients with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) support the involvement of the α4 subunit of nAChR in this process [11] . Increased levels of the CHRNA7 transcript in the hippocampus, as well as in the lymphocytes, of AD patients have been reported [19, 20] , suggesting that the elevation in CHRNA7 gene expression may be associated with AD, and that the receptors localized in PBLs correspond to the same receptors in the brain. Recent observations, however, have revealed that the CHRNA7 transcripts found in PBLs are products of the gene encoding the duplicated α7 subunit of nAChR (CHRFAM7A), but not the "classic" CHRNA7 [51] . Contradictory results were also obtained in the frontal cortex of AD patients showing no differences in α-bungarotoxin binding [7, 49] , and a significant decrease of α7 subunit levels [14] . The human gene encoding the α7 subunit is partially duplicated, with both loci mapp ing to the chromosome 15q13-q14 region and approximately 1.5 Mb apart [38] . Since the two related genes encoding the α7 subunit (CHRNA7 and CHRFAM7A) are present in the human genome, two isoforms of the α7 subunit (α7 and dupα7, respectively) and the corresponding transcripts have been identified. Therefore, the search for mutations of the α7 subunit gene is complicated, since exons 5 through 10 are duplicated and give rise to five new exons (D´-D-C-B-A), which are expressed in the brain and peripheral tissues [7, 14, 19, 20, 38, 49, 51] . Gault et al. [16] demonstrated that the TG deletion polymorphism (c.497-498delTG; rs67158670) causes a shift in the reading frame, introduces a stop codon in exon 6, and results in a non-functional α7 subunit. This -2bp allele is present only in the duplicated exon 6 of the CHRFAM7A gene. It has been shown that the presence of the 2bp deletion in the CHRFAM7A gene may influence the risk of developing bipolar (BP) and major depressive (MD) disorders [23, 27] . According to a recent study, the 2bp deletion polymorphism is a risk factor for auditory sensory gating deficit, which charac terizes the majority of patients with chronic schizophrenia [37] . The impact of the α7 AChR partial gene duplication and the -2bp variant on the development of epileptic symptoms remains to be determined.
Aim of the study
Several mutations of the CHRNA4 gene were associated with ADNFLE and the c.851C>T (S284L) mutation was identified in a Caucasian family with ADNFLE [40] , in which PET analysis has demonstrated decreased density of nAChR in the prefrontal cortex of the pro band's brain [36] . Since the α7 nAChR subunit is expressed in PBLs, we decided to investigate the CHRFAM7A transcript level in the CD4 + T-lymphocytes from ADNFLE patients and healthy individuals to look for possible involvement of this gene's expression in the pathogenesis of ADNFLE. Since earlier studies have suggested that a deletion in the 15q13-q14 lo cus might cause epilepsy, we compared the CHRNA7 and CHRFAM7A sequences, and investigated the relation between the c.497-498delTG polymorphism and ADNFLE.
Material and methods
P Pa at ti ie en nt ts s
Peripheral blood samples were taken from three nonsmoking ADNFLE individuals of the same family: the male patient (proband), 28 years of age, his father, and the sister of his father (the pedigree is shown in Fig. 1 ). All patients harbour the c.851C>T mutation of the CHRNA4 gene (α4-S284L) and suffer from ADNFLE [40] .
The proband (III-3 in Fig. 1 ) was diagnosed and treated in the Department of Developmental Neurology, Poznan University of Medical Sciences in Poznan (Poland). On the basis of neurological examination before treatment with carbamazepine, the patient had 20-30 seizures per night, manifesting as simple motor acts such as head scratching, limb flexion, the sensation of being out of breath, tonic stiffening, and vocalisation. Upon treatment with carbamazepine (600 mg/day), the frequency of seizures decreased to 2 to 3, twice Proband's father (II-2 in Fig. 1 ). At the age of five, nocturnal seizures described as generalized tonic-clonic convulsions were diagnosed. Interictal EEGs and cerebral CT examinations showed no abnormalities and he has never been treated for epilepsy. At present, motor acts with the involvement of multiple body segments such as gross body movements, change in body position and/or rhythmic movements (lasting for 5 to 10 s) can be observed during the night.
Sister of proband's father (II-4 in Fig. 1 ). Since the age of two she has been treated for epilepsy. The seizures (verbal manifestation and sometimes urinary incontinence) occurred in clusters of about ten a night, and began soon after falling asleep. When she was five, the seizures were observed during the day in the form of general tonic convulsions. Interictal surface EEGs were normal and cerebral CT showed no abnormalities. She was treated with phenobarbital, carbamazepine, valproate and phenytoin, and the frequency and duration of seizures decreased but they were not eliminated. At present, she still has two to three nocturnal seizures lasting for 3 to 5 s.
As controls, 10 healthy male non-smoking blood donors aged 25 to 30, without any neurological disorders, were used.
Written consent of all study participants was obtained, and the study was approved by the local Ethics Committee.
I Is so ol la at ti io on n o of f g ge en no om mi ic c D DN NA A a an nd d c co om mp pa ar ri is so on n o of f C CH HR RN NA A7 7 a an nd d C CH HR RF FA AM M7 7A A s se eq qu ue en nc ce es s In order to analyse the structure of CHRNA7 and its partially duplicated form (CHRFAM7A), genomic DNA was isolated from PBLs with the use of Blood DNA Prep Plus (A&A Biotechnology, Poland). The sequences of CHRNA7 and CHRFAM7A were compared (http://www. esembl.org), and the fragments that differ between the two genes were identified. These fragments are localized upstream from exon 6, at the 2782 and 3005 positions of CHRNA7 and CHRFAM7A, respectively. In order to amplify these fragments by polymerase chain reaction (PCR), a common pair of the following primers flanking the DNA sequence that is different in the two genes was designed: GCTGGGGTTTTTGATCTTT-TAG (forward) and GTGGAGTGGTGAGTGGTGTG (reverse). Following PCR amplification, fragments of the CHRNA7 and CHRFAM7A genes were separated by agarose gel electrophoresis and their molecular size was determined.
G Ge en no ot ty yp pi in ng g a an nd d s se eq qu ue en nc ci in ng g o of f t th he e --2 2b bp p p po ol ly ym mo or rp ph hi is sm m DNA used for genotyping of the -2bp polymorphism was extracted from PBLs. The CHRFAM7A fragment harbouring the polymorphism was PCR amplified using the following primers: TCTTCTGTTTCCATCACCCACACA (forward) and GCTTTCTTCCAGGCGGTTAGTCC (reverse). The PCR fragments, 226bp in length, were subjected to polyacrylamide gel electrophoresis (PAGE) in 10% acrylamide gel (500 V, 100 mA, 25 W for 60 min) and were visualized by silver-staining. Templates for direct sequencing were generated using the same primers as those used for amplification. The reaction was conducted using a sequencing kit (BigDye Terminator v3.1. Cycle Sequencing system) and an automated DNA sequencer (ABI PRISM310, Applied Biosystems, USA).
S Sy yn nt th he es si is s a an nd d s se eq qu ue en nc ci in ng g o of f c cD DN NA A f fr ro om m r re es st ti in ng g a an nd d a ac ct ti iv va at te ed d C CD D4 4 + + T T--l ly ym mp ph ho oc cy yt te es s In order to identify the transcripts encoded by the fragments that are present in CHRNA4 and CHRFAM7A, RNA was isolated from the CD4 + T-lymphocytes according to the original protocol of Chomczynski and Sacchi [5] . Immediately after isolation, one fifth of the poly-A + mRNA eluted from oligo(dT) 25 column was reverse transcribed into cDNA with the use of M-MLV reverse transcriptase (Invitrogen, USA), and the obtained cDNA was used as a template for amplification of the fragment spanning exons 5 and 6 of CHRNA4 and exons 6 and 7 of CHRFAM7A. In order to differentiate the cDNAs amplified, the following primers (all from OLIGO IBB, Poland) were designed for amplification of the different exons of CHRNA4 and CHRFAM7A, CCAGTACATTGCAGACCACCT (forward), TGAACATCCA-GAGGAAGATGC (reverse) and CTGAAG-TTTGGGTC-CTGGTC (forward), AAGGTGCATCGGGGTAGG (reverse), respectively. The amplified products of CHRFAM7A were separated by PAGE in 10% polyacrylamide gel, followed by staining with ethidium bromide. Fragments of the ) appropriate length were then excised from the gel, re-amplified, purified, and subjected to sequencing with the use of BigDye Terminator v3.1. Cycle Sequencing system and ABI PRISM310 sequencer (Applied Biosystems, USA).
P PC CR R a am mp pl li if fi ic ca at ti io on n o of f c cD DN NA A f fr ro om m C CD D4 4 + + T T--l ly ym mp ph ho oc cy yt te es s
In order to detect the CHRNA4 and CHRFAM7A transcripts and estimate the melting temperature (T m ) of the amplified fragments, qualitative analysis was performed. Quantitative analysis (RQ-PCR) was conducted using the LightCycler real-time PCR system (Roche Diagnostics, Mannheim, Germany) using SYBR ® Green I as the detection dye. The relative abundance of target cDNA in each sample was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal standard and the results were elaborated using the Microsoft Excel computer program.
Results
In order to compare the primary structure of CHRNA7 and CHRFAM7A in patients with ADNFLE and healthy individuals, analysis of genomic DNA fragments, amplified with the use of the same primers, was conducted. Specific amplification products of CHRNA7 (356bp in size) and CHRFAM7A (633bp in size) were obtained in patients and healthy individuals.
Genotyping of the -2bp CHRFAM7A polymorphism (rs67158670) was conducted by PAGE analysis of the PCR products in 10% polyacrylamide gel. Among the genotypes found in the control group, there were seven individuals with the c.497-498delTG polymorphism and three with the wild-type/wild-type genotype of CHRFAM7A. Among the genotypes found in the pa tients, the -2bp alleles were present in all individuals. Sequencing analysis ( Fig. 2A) of the relevant region of exon 6 in the proband showed a heterozygous c.497-498delTG polymorphism.
In the CD4 + T-lymphocytes of all healthy individuals the fragment of CHRFAM7A cDNA of the expected size (170bp) was detected. This fragment was ex cised from the gel, purified, re-amplified and sequenced. The nucleotide sequence of the purified product was identical to the sequence joining exons 6 and 7 (Fig. 2B) .
In an attempt to identify the CHRFAM7A transcript in the CD4 + T-lymphocytes of the ten healthy individuals, the T m of all amplified fragments was measured with the use of LightCycler. The T m was almost identical in all healthy individuals and amounted to 86.0+/ -0.1°C (Fig. 3A) . In the CD4 + T-lymphocytes of the healthy individuals, the levels of the CHRFAM7A transcript varied from 6.16 x 10 4 to 1.67 × 10 5 copies per 10 3 cells (Fig. 3B) , the average number being 1.25 ± 0.36 × 10 5 copies per 10 3 cells. This suggests that the basal expression of CHRFAM7A in these CD4 + T-lymphocytes was about 100 copies per cell. This result implies a legitimate expression of CHRFAM7A in these cells and a possible contribution of the dupα7 subunit to the assembly of the Ca 2+ -channel in these cells.
Qualitative analysis with the use of real time PCR showed lack of this transcript in the lymphocytes of patients with ADNFLE, providing evidence that CHRFAM7A is expressed in the CD4 + T-lymphocytes of the healthy individuals tested, but not in the individuals with ADNFLE (Fig. 4) . The transcript of GAPDH (which is constitutively expressed) was identified in all samples taken from healthy individuals as well as those of the patients with ADNFLE. The T m of all amplified fragments amounted to 82.0+/-0.1°C (Fig. 4) . The possibility that some material was lost during the procedure can be excluded, since GAPDH transcript was detected in the CD4 + T-lymphocytes of the patients as well as in the healthy individuals at similar levels. To ensure the integrity of these results, an additional housekeeping gene, encoding beta-actin (ACTB), was used in a qualitative real time PCR study (Fig. 4) .
Qualitative and quantitative analysis with the use of the LightCycler system, excluded the presence of the CHRNA4 transcript in CD4 + T-lymphocytes of all individuals tested.
Discussion
Expression of nAChR subunits varies across brain regions, with the most abundant α4 subunit being highly expressed in the thalamus and cortex [42] and the α7 subunit in the hippocampus, lateral and medial geniculates, and the reticular thalamic nucleus, a brain region frequently associated with pathophysiology of epilepsy [4] . The presence of CHRNA7 transcript in various blood cells, including T-lymphocytes, has also been demonstrated [44] . Although the expression pattern of this gene varied in PBLs taken from different donors, Sato et al. [44] have demonstrated expression of the α2, α5, and α7 subunits and no expression of the α3, α4, β3, and β4 subunits in these cells. Most of the recent studies have shown that neuron-type nAChR subunits are expressed in PBLs, thymocytes, and human leukemic cell lines [25, 44] . However, Hiemke et al. [21] and Benhammou et al. [2] determined, by RT-PCR followed by Southern blot analysis, the expression of the α3 and α4 subunits in the T-lymphocytes. In our study, no CHRNA4 transcript in the CD4 + T-lymphocytes was detected in all samples taken from 10 healthy individuals and 3 ADNFLE patients, confirming the data published by Sato et al. [44] regarding the lack of peripheral expression of this gene. Consistent with our attempts to identify a mutation of CHRNA4 responsible for ADNFLE in a Caucasian family [40] , we extended our studies and estimated the level of CHRFAM7A transcripts in the CD4 + T-lymphocytes of both the patients and the healthy individuals used as controls, since CHRNA7 is not expressed in PBLs [51] . The cDNA primers used in our study were designed to amplify a region between exon 6 and exon 7 of CHRNA7 that is conserved between these two genes. In the control group, the basal expression of 
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A transcript coding for a partially duplicated form of α7 nicotinic acetylcholine receptor is absent from the CD4 + T-lymphocytes of patients with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
CHRFAM7A was about 100 copies per cell. The results of our study showed that, as opposed to the healthy individuals, there was no expression of CHRFAM7A in the ADNFLE patients harbouring the S284L substi tution in the α4 subunit. This suggests that there might be a link between the expression of CHRFAM7A and the occurrence of the symptoms of ADNFLE. Most recently, de Lucas-Cerrillo et al. [9] revealed that basal CHRFAM7A mRNA levels are higher in macrophages. Previously, Benfante et al. [1] showed that both the mRNA and protein products of CHRFAM7A were reduced in primary monocytes and macrophages after lipopolysaccharide (LPS) treatment. This transcriptional down-regulation was mediated by a direct mechanism dependent on NFκB, suggesting that dupα7 may specifically participate in the inflammatory response of the innate immune system. Current know ledge indicates that functional cross-talk between presynaptic receptors may occur if both receptors are ac tivated by the same neurotransmitter [28] . This interaction will finally produce, through different mechanisms, an integrated response which generates synergistic or antagonistic effects. It has been amply demonstrated that a variable response occurs with different subtypes of heteromeric nAChRs [28] ; however, no evidence has so far been produced to support the involvement of the homomeric α7 nAChRs. This could be particularly relevant because, as far as the functional diversity of nAChR subtypes is concerned, recent evidence supports the possibility that α7 and α4β2 nAChR subtypes, which are differently permeable to Ca 2+ ions, trigger neurotransmitter release via different mechanisms [10] . In our proband with ADNFLE, the PET study of the distribution of the mutated receptor revealed a lower number of α4β2 nAChR in the right prefrontal region of the brain [36] . This confirms that low ex pression of these subunits might be connected with decreased expression of other nAChR subunits, including those encoded by CHRNA7. In the case of ADNFLE, however, no link between clinical symptoms and brain expression of the gene encoding the α7 subunit or the dupα7 isoform has been demonstrated. Decreased mRNA levels of the duplicated form of α7 nAChRs in lymphocytes and in the hippocampus of schizophrenic patients have been reported, suggesting that a genetic defect in CHRFAM7A expression may be associated with the pathogenesis of schizophrenia [15, 34] . A hypothesis was put forward that the level of CHRFAM7A mRNA in PBLs might reflect expression of the α7 nAChRs in the brain and that it might constitute a marker of some psychiatric disorders [34] . Lower expression levels of the gene encoding the α7 nAChR subunit in the frontal lobe of cerebral cortex of pa tients with schizophrenia seem to support this hypothesis [15] . To date, it is difficult to explain why the CHRFAM7A gene is not expressed in CD4 + T-lymphocytes of pa tients with ADNFLE, while it is expressed in the same cells of normal individuals. The analysis of the clinical variability presented by Steinlein et al. [48] suggested that the risk for additional major neurological and psychiatric features might be increased for ADNFLE patients with certain nAChR mutations. However, major neurological features such as schizophrenia-like symptoms, mental retardation or cognitive deficits have been described only in a few families [48] . A relatively high expression of CHRFAM7A in T-lymphocytes of the healthy individuals studied, as well as lack of expression of this gene in the same cells of ADNFLE patients, were not a result of contact with nicotine, since all individuals tested were non-smokers and never smoked. We took note of smoking as a factor since the study by Kimura et al. [26] demonstrated that nicotine decreased the mRNA level of CHRFAM7A in a T-lymphocyte model cell line. We also excluded the effect of antiepileptic drug (AED), carbamazepine, on CHRFAM7A expression, since there was no expression of this gene in either the two patients who did not take this drug or in the proband who was treated with carbamazepine. Genetic factors also appear to be significant in disturbances in ratios of the sulphur-containing amino acids, homocysteine (Hcy) and methionine (Met) as well as asymmetric dimethylarginine (ADMA) and arginine (Arg), in epileptic patients treated with variable AEDs. Our previous study [46] demonstrated that AED pharmacotherapy in epileptic patients leads to increase in Hcy and ADMA levels and the feedback control of Hcy over ADMA was disturbed. It is suggested that polymorphisms of genes related to Hcy-to-Met metabolism may have an effect on the regulation of the Hcy and ADMA levels in epileptics treated with AEDs.
Recently, a 15q13.3 microdeletion syndrome (OMIM ID: 612001) has been identified in 0.2-0.3% of individuals with mental retardation and epilepsy, as well as in schizophrenia, autism and some other neuropsychiatric disorders [45, 47] . The region on 15q13.3 that contains the 1.5-Mb deletion harbours at least seven genes, including CHRNA7. Presently, the 15q13.3 microdeletion has been deemed the main risk factor for IGEs [18] . However, the underlying genetic alterations remain largely unknown in the vast majority of individuals with IGEs [8, 30] . In our patients with ADNFLE, as well as in the healthy individuals, analysis of genomic DNA fragments revealed specific amplification products of CHRNA7 and CHRFAM7A, indicating that the absence of the CHRFAM7A transcript from T-lymphocytes of the ADNFLE patients was not a result of the 15q13.3 microdeletion. The 2bp deletion in the partially duplicated α7 nAChR gene should also be excluded as the reason of lack of CHRFAM7A expression in ADNFLE patients, since CHRFAM7A was expressed in CD4+ T-lymphocytes of healthy individuals carrying this polymorphism.
The c.497-498delTG polymorphism is associated with auditory sensory gating deficit characterizing schizophrenic patients [37] , and may be implicated in BP Agata Rozycka, Jolanta Dorszewska, Barbara Steinborn, Bartosz Kempisty, Margarita Lianeri, Kamila Wisniewska, Paweł P. Jagodzinski A transcript coding for a partially duplicated form of α7 nicotinic acetylcholine receptor is absent from the CD4 + T-lymphocytes of patients with autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and MD disorders [23, 27] . The study described by Hong et al. [27] indicated that a genotype variant with greater than two -2bp allele copy number is unlikely. We conducted the c.497-498delTG polymorphism analysis in three patients with ADNFLE and in ten healthy individuals, and -2bp alleles were found in all ADFLE patients as well as in seven members of the control group. This result suggests that the -2bp polymorphism or a nearby polymorphism may only play a secondary role in the pathogenesis of ADNFLE. Determination of the functional impact of the c.497-498delTG CHRFAM7A variant on the nervous system needs further exploration.
Conclusions
ADNFLE is a familial partial epilepsy syndrome and the first human idiopathic epilepsy known to be re lated to specific gene defects. However, there are not many familial cases of ADNFLE with known genetic mutations. Clinically available molecular genetic testing reveals mutations in three genes: CHRNA4, CHRNB2 and CHRNA2. Mutations in CHRNA4 have been found in families from different countries; the S280F in Australian, Spanish, Norwegian and Scottish families, and the S284L in Japanese, Korean, Lebanese and Polish families. Although no link between clinical symptoms of ADNFLE and the genes encoding the α7 or dupα7 subunits has been demonstrated to date, the results of our study showed that, as opposed to healthy individuals, there was no expression of CHRFAM7A in the CD4 + T-lymphocytes of the ADNFLE proband and his two family members harbouring the S284L substitution in the α4 nAChR subunit. Since the expression of the α4β2 nAChR in the right prefrontal region of the proband's brain was decreased, our results confirm that low expression of these subunits might be connected with expression of other nAChR subunits, including those encoded by CHRFAM7A. This suggests that there might be a link between the expression of CHRFAM7A and the occurrence of the symptoms of ADNFLE.
We do recognise that our study was performed in only one family and has a limited scope due to the unavailability of the genetic material of other families with ADNFLE with known genetic mutations in nAChRs. However, we believe that the documentation of our findings is significant as pertains to the genetic and expressive status of the CHRNAM7A gene in this particular family with ADNFLE. The results of our study, although made on a small group of ADNFLE patients, seem convincing since the CHRFAM7A transcript from the purified CD4 + T-lymphocytes was analysed and the presence of other cell types can be excluded. Moreover, the use of real-time qPCR instead of the routine PCR technique allowed us to precisely quantify the number of transcript copies. This is the first report showing that the expression pattern of CHRFAM7A can be demonstrated in CD4 + T-lymphocytes of the studied healthy individuals, and that there is no expression of this gene in the same cells of the studied patients with ADNFLE, as verified using the RT-qPCR technique. If the level of the CHRFAM7A transcript in the CD4 + T-lymphocytes reflects the expression of nAChR in the brain, it may constitute a biological marker of the disease. However, to substantiate our findings, further studies on a much larger group of ADNFLE patients with diagnosed nAChR mutations are required. Similarly, a large-scale association study is needed to indicate whether there is some evidence supporting the association of the CHRFAM7A 2-bp deletion polymorphism with ADNFLE.
